Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

13.86 -0.14 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Lost Money in ChemoCentryx, Inc.?
From Gibbs Law Group
Via Business Wire
News headline image
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
News headline image
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces ChemoCentryx, Inc. (CCXI) Sued for Misleading Investors
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders 
Via EIN Presswire
Topics Lawsuit
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news. Obalon Therapeutics, Inc. (NASDAQ: OBLN) gained 35% to $2.97. Cue... 
Via Benzinga
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Notice of Lead Plaintiff Deadline for Shareholders in the ChemoCentryx, Inc. Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
70 Biggest Movers From Friday ↗
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
News headline image
SHAREHOLDER ALERT: Robbins LLP Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop ↗
Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Stocks Reverse Course, Investors Look at Flip Side of Economic Data ↗
While a lackluster April jobs report initially sunk stocks this morning, the indexes are bouncing back as investors speculate that the disappointing data could mean the continuation of easy policies... 
Via Talk Markets
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Yield10 Bioscience (NASDAQ:YTEN) stock increased by 20.74% to $10.36 during Friday's regular session. As of 12:30 EST, Yield10 Bioscience's stock is... 
Via Benzinga
News headline image
Why ChemoCentryx Stock Is Cratering Again Today ↗
Investors aren't optimistic after an FDA advisory committee vote for avacopan. 
Via The Motley Fool
News headline image
Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide ↗
Midway through trading Friday, the Dow traded up 0.45% to 34,705.48 while the NASDAQ rose 1.35% to 13,816.46. The S&P also rose, gaining 0.77% to 4,233.93. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Why ChemoCentryx Shares Are Plunging Today ↗
ChemoCentryx (NASDAQ: CCXI) shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated... 
Via Benzinga
News headline image
56 Stocks Moving In Friday's Mid-Day Session ↗
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April ↗
Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges ↗
Yesterday, the FDA’s Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for ChemoCentryx Inc... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021 ↗
Upgrades Loop Capital upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Hold to Buy. In the first quarter, Roku showed an EPS of $0.54, compared to $0.45 from... 
Via Benzinga
News headline image
ChemoCentryx Stock Loses Half Its Value; Is This The Final Nail For Its Drug? ↗
A panel of experts was split Thursday on whether to recommend approval for ChemoCentryx's autoimmune disease drug — and CCXI stock plummeted Friday. 
Via Investor's Business Daily
News headline image
10 Biggest Price Target Changes For Friday ↗
Stifel boosted Wayfair Inc. (NYSE: W) price target from $200 to $280. Wayfair shares rose 1.7% to $290.91 in pre-market trading. RBC Capital raised ViacomCBS Inc. (NASDAQ: VIAC... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5... 
Via Benzinga
News headline image
Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate ↗
The FDA’s Arthritis Advisory Committee voted 10 for and 8 against the approval of ChemoCentryx Inc’s (NASDAQ: CCXI) investigational drug... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.